What is the core reason ReNerve (ASX:RNV) secured the new funding facility?

ReNerve (ASX:RNV) secured the funding facility to support its ongoing commercialisation strategy, expand its product portfolio, and fund general corporate purposes.

What is the financial layout of the ReNerve (ASX:RNV) agreement?

ReNerve (ASX:RNV) executed a convertible note funding agreement for up to $5 million over a three-year availability period. The arrangement begins with an initial gross drawdown of $1.6 million.

How does this facility impact the share structure of ReNerve (ASX:RNV)?

The facility limits the maximum share dilution from the first drawdown to 16,054,394 shares issued under convertible securities. ReNerve (ASX:RNV) will issue accompanying options subject to approval at the company's next general meeting.

What are the primary geographic markets targeted by ReNerve (ASX:RNV) for this funding?

ReNerve (ASX:RNV) will use the capital to fund sales and distribution activities in the United States alongside broader international market development initiatives.

How did the market react to the funding announcement by ReNerve (ASX:RNV)?

Following the announcement, the ReNerve (ASX:RNV) share price remained unchanged at $0.081. This capital management update follows a prior cash influx in February 2026, when the business received an $517,000 research and development tax incentive refund.

Image for illustrative purposes only. Not a real photo.

ReNerve secures $5M funding facility

Written by Heidi Cuthbert Published Jul 9, 2026, 5:53 AM

ReNerve has executed a convertible note funding agreement with RiverFort Global Opportunities PCC for up to $5 million.
The company will receive an initial gross drawdown of $1.6 million, while its share price remained unchanged.
The capital will support ongoing commercialisation, product portfolio expansion, and sales distribution activities in the United States.

ReNerve (ASX:RNV) has secured a convertible note funding facility of up to $5 million to support its commercialisation strategy.

This three-year arrangement follows an $517,000 research and development tax incentive refund received by the business in February.

“This funding facility provides ReNerve with important financial flexibility as we continue to advance our commercial and strategic objectives,” said ReNerve CEO Dr Julian Chick.

The initial $1.4 million in net cash proceeds after fees and discounts.

Following the announcement, the ReNerve share price was unchanged at $0.081.

The business stated that the funding will also drive marketing expansion and clinical development initiatives within international markets.

The transaction follows the recent securement of regulatory marketing approval for the company's nerve repair products in Indonesia.

ReNerve secures $5M funding facility

Frequently asked questions

Assets related to this article